Klaus Pors

1.3k total citations
61 papers, 1.0k citations indexed

About

Klaus Pors is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Klaus Pors has authored 61 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 18 papers in Oncology and 17 papers in Cancer Research. Recurrent topics in Klaus Pors's work include Cancer therapeutics and mechanisms (19 papers), Pharmacogenetics and Drug Metabolism (13 papers) and Cancer, Hypoxia, and Metabolism (9 papers). Klaus Pors is often cited by papers focused on Cancer therapeutics and mechanisms (19 papers), Pharmacogenetics and Drug Metabolism (13 papers) and Cancer, Hypoxia, and Metabolism (9 papers). Klaus Pors collaborates with scholars based in United Kingdom, Italy and Spain. Klaus Pors's co-authors include Laurence H. Patterson, Jan S. Moreb, Mark Searcey, Paul M. Loadman, Helen M. Sheldrake, Steven D. Shnyder, Goreti Ribeiro Morais, John A. Hartley, Marco L. Lolli and Paul Teesdale‐Spittle and has published in prestigious journals such as Cancer Research, Oncogene and Chemical Communications.

In The Last Decade

Klaus Pors

56 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Klaus Pors United Kingdom 20 563 264 250 194 171 61 1.0k
Drew Adams United States 18 706 1.3× 172 0.7× 180 0.7× 174 0.9× 163 1.0× 44 1.1k
Tanya Coleman United Kingdom 17 589 1.0× 282 1.1× 147 0.6× 88 0.5× 115 0.7× 28 1.1k
Eric Trottier Canada 11 737 1.3× 235 0.9× 148 0.6× 312 1.6× 245 1.4× 13 1.1k
Ted W. Johnson United States 18 790 1.4× 156 0.6× 395 1.6× 64 0.3× 82 0.5× 28 1.6k
Kiyohiro Nishikawa Japan 21 767 1.4× 397 1.5× 348 1.4× 150 0.8× 81 0.5× 56 1.4k
Ross Weatherman United States 16 662 1.2× 230 0.9× 338 1.4× 68 0.4× 232 1.4× 25 1.3k
Eric Van Quaquebeke Belgium 8 705 1.3× 136 0.5× 228 0.9× 74 0.4× 126 0.7× 21 1.1k
Mohammed Jaffar United Kingdom 19 672 1.2× 181 0.7× 340 1.4× 234 1.2× 55 0.3× 39 1.3k
Lalji K. Gediya United States 19 773 1.4× 168 0.6× 373 1.5× 153 0.8× 98 0.6× 26 1.3k
Haoliang Yuan China 21 697 1.2× 312 1.2× 282 1.1× 58 0.3× 61 0.4× 71 1.2k

Countries citing papers authored by Klaus Pors

Since Specialization
Citations

This map shows the geographic impact of Klaus Pors's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus Pors with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus Pors more than expected).

Fields of papers citing papers by Klaus Pors

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus Pors. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus Pors. The network helps show where Klaus Pors may publish in the future.

Co-authorship network of co-authors of Klaus Pors

This figure shows the co-authorship network connecting the top 25 collaborators of Klaus Pors. A scholar is included among the top collaborators of Klaus Pors based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaus Pors. Klaus Pors is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wahajuddin, Muhammad, et al.. (2024). The Capacity of Drug-Metabolising Enzymes in Modulating the Therapeutic Efficacy of Drugs to Treat Rhabdomyosarcoma. Cancers. 16(5). 1012–1012. 1 indexed citations
2.
Riches‐Suman, Kirsten, Klaus Pors, Matthew A. Addicoat, et al.. (2024). Encapsulation and Delivery of Mitoxantrone Using Zirconium-Based Metal–Organic Frameworks (MOFs) and Their Cytotoxic Potential in Breast Cancer Cells. Applied Sciences. 14(5). 1902–1902. 5 indexed citations
3.
Ugail, Hassan, et al.. (2023). Deep Transfer Learning-Based Approach for Glucose Transporter-1 (GLUT1) Expression Assessment. Journal of Digital Imaging. 36(6). 2367–2381. 1 indexed citations
4.
Pippione, Agnese Chiara, Stefano Sainas, Barbara Rolando, et al.. (2022). New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold. European Journal of Medicinal Chemistry. 237. 114366–114366. 11 indexed citations
5.
Dumbell, Rebecca, Samantha L. McLean, Sriharsha Kantamneni, et al.. (2022). The Chemerin-CMKLR1 Axis is Functionally important for Central Regulation of Energy Homeostasis. Frontiers in Physiology. 13. 897105–897105. 21 indexed citations
6.
Karu, Kersti, Goreti Ribeiro Morais, Helen M. Sheldrake, et al.. (2021). Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds. Bioorganic & Medicinal Chemistry. 40. 116167–116167. 3 indexed citations
7.
Morais, Goreti Ribeiro, et al.. (2021). Cytochrome P450 Binding and Bioactivation of Tumor-Targeted Duocarmycin Agents. Drug Metabolism and Disposition. 50(1). 49–57. 9 indexed citations
8.
Rosell, Glòria, et al.. (2018). Synthesis and biological properties of aryl methyl sulfones. Bioorganic & Medicinal Chemistry. 26(14). 4113–4126. 22 indexed citations
9.
Pippione, Agnese Chiara, Davide Bonanni, Marcella Sini, et al.. (2018). Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid. European Journal of Medicinal Chemistry. 150. 930–945. 40 indexed citations
10.
Webber, Jason & Klaus Pors. (2018). Introduction of the special issue "How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?". Journal of Cancer Metastasis and Treatment. 4(8). 45–45. 1 indexed citations
11.
Nagare, Rohit P., et al.. (2017). Therapeutic antibodies against cancer stem cells: a promising approach. Cancer Immunology Immunotherapy. 66(11). 1383–1398. 14 indexed citations
12.
Sellars, Jonathan D., et al.. (2016). Rational Development of Novel Activity Probes for the Analysis of Human Cytochromes P450. ChemMedChem. 11(11). 1122–1128. 7 indexed citations
13.
Allison, Simon J., Haneen A. Basheer, Goreti Ribeiro Morais, et al.. (2016). Polysialic acid sustains cancer cell survival and migratory capacity in a hypoxic environment. Scientific Reports. 6(1). 33026–33026. 46 indexed citations
14.
Pors, Klaus & Jan S. Moreb. (2014). Aldehyde dehydrogenases in cancer: an opportunity for biomarker and drug development?. Drug Discovery Today. 19(12). 1953–1963. 88 indexed citations
15.
Perry, Tracey, Sarah Berhane, Ceri Oldreive, et al.. (2014). The dual-acting chemotherapeutic agent Alchemix induces cell death independently of ATM and p53. Oncogene. 34(25). 3336–3348. 6 indexed citations
16.
Pors, Klaus, Paul M. Loadman, Steven D. Shnyder, et al.. (2013). Colon Cancer–Specific Cytochrome P450 2W1 Converts Duocarmycin Analogues into Potent Tumor Cytotoxins. Clinical Cancer Research. 19(11). 2952–2961. 46 indexed citations
17.
Sutherland, Mark, Jason H. Gill, Paul M. Loadman, et al.. (2012). Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder. Molecular Cancer Therapeutics. 12(1). 27–37. 36 indexed citations
18.
Smith, Paul J., Marie Wiltshire, Sally C. Chappell, et al.. (2012). Kinetic analysis of intracellular Hoechst 33342—DNA interactions by flow cytometry: Misinterpretation of side population status?. Cytometry Part A. 83A(1). 161–169. 13 indexed citations
19.
Cooper, Patricia A., et al.. (2011). Use of the hollow fiber assay for the evaluation of DNA damaging agents. Journal of Pharmacological and Toxicological Methods. 64(3). 226–232. 4 indexed citations
20.
Ghosh, Nandita, Helen M. Sheldrake, Mark Searcey, & Klaus Pors. (2009). Chemical and Biological Explorations of the Family of CC-1065 and the Duocarmycin Natural Products. Current Topics in Medicinal Chemistry. 9(16). 1494–1524. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Drew Adams Breakdown of academic impact, for papers by Tanya Coleman Breakdown of academic impact, for papers by Eric Trottier Breakdown of academic impact, for papers by Ted W. Johnson Breakdown of academic impact, for papers by Kiyohiro Nishikawa Breakdown of academic impact, for papers by Ross Weatherman Breakdown of academic impact, for papers by Eric Van Quaquebeke Breakdown of academic impact, for papers by Mohammed Jaffar Breakdown of academic impact, for papers by Lalji K. Gediya Breakdown of academic impact, for papers by Haoliang Yuan
Rankless by CCL
2026